French National Cohort of Patients With PRSS1 Mutations
Assistance Publique - Hôpitaux de Paris
800 participants
Nov 10, 2024
OBSERVATIONAL
Conditions
Summary
The diagnosis of hereditary pancreatitis (PH) is based on a genetic criterion - detection of a mutation in the PRSS1 gene or on a genealogical criterion - the presence of chronic pancreatitis in at least 2 first-degree relatives or at least 3 relatives in the second degree, in the absence of other identified predisposing factors (notably chronic alcohol consumption). It is now recommended to seek PH in cases of pancreatitis of unknown origin in a young patient or with a family history. In this study, patients carrying a PRSS1 mutation will be identified from the patient lists of the three French genetics laboratories (Brest University Hospital, Cochin-Paris University Hospital, Lille University Hospital) carrying out PRSS1 gene analysis. Patients will be included by the doctors currently treating them. The aim of the study is to assess the incidence of pancreatic adenocarcinoma in the cohort and describe the natural history of hereditary pancreatitis linked to a mutation in PRSS1.
Eligibility
Inclusion Criteria2
- Being a carrier of a known genetic mutation in the PRSS1 gene coding for cationic trypsinogen
- Be followed in one of the participating centers
Exclusion Criteria1
- Opposition to data collection, expressed by the patient or one of their legal representatives
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients seen as part of their follow-up will be offered to participate in the study. Their participation will consist of collecting their health data from their medical file and completing questionnaires.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07413029